Tuebingen/Tuttlingen — SHS Gesellschaft fuer Beteiligungsmanagement, MBG Baden-Württemberg and VC Fonds BW announced that Emerging Implant Technologies GmbH (EIT), a manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, has been acquired by Johnson & Johnson Medical GmbH. SHS became EIT’s lead investor in September 2016. Since then the Tuebingen based medtech specialist has subsequently supported the company’s growth strategy. The financial terms of the deal are undisclosed.
“SHS’s objective was to support EIT on their path to increased growth. This includes the development of the company’s innovative product portfolio as well as entering new countries. We’re delighted to have had such a successful partnership with EIT and its employees. We look forward to see EIT’s unique products and Cellular Titanium® technology benefit from DePuy Synthes global commercial infrastructure and products. We wish EIT all the best in their future development and trust that the company is in good hands with its new owners”, says Dr. Bernhard Schirmers, Managing Partner of SHS, lead investor with EIT.
Guntmar Eisen, Founder and Chief Executive Officer of EIT says: “The EIT team is passionate about the work we do every day to develop 3D-printed titanium spinal implants. We are proud of what we have achieved with the EIT cellular titanium cages and we are excited to bring this innovative technology to DePuy Synthes, and to customers around the world.”
To learn more about the announcement, click here: https://www.prnewswire.com/news-releases/johnson–johnson-medical-gmbh-acquires-emerging-implant-technologies-gmbh-to-enhance-global-offering-of-interbody-spine-implants-300710822.html
About SHS Gesellschaft für Beteiligungsmanagement mbH
Germany (Tuebingen) based SHS Gesellschaft für Beteiligungsmanagement was founded in 1993 and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations in the DACH-region, Benelux-countries and Scandinavia. Medical device investments made by the sector specialist SHS include for example German company phenox, which specializes in technologies for the treatment of neurovascular diseases, Austrian rehabilitation robotics company Tyromotion, and the Swiss manufacturer of cardiology products SIS Medical. In its fifth fund’s first closing in July 2018 SHS has received capital commitments of over €90 million. Investors can invest in SHS V until final closing (target €150 million). The company invests up to 30 million euros in equity. Reinhilde Spatscheck, Dr. Bernhard Schirmers, Hubertus Leonhardt and Uwe Steinbacher are the Managing Partners at SHS.